A practical reference on pentapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Autologous fat (fat tissue transferred from elsewhere in the body). Teflon. Bovine glutaraldehyde cross-linked collagen (collagen from cows). Carbon-coated zirconium/graphite beads ("Durasphere"). Polydimethylsiloxane elastomer (silicone) biomaterial implants ("PTQ implant"). Dextranomer in non-animal stabilised hyaluronic acid ("Solesta", "NASHA Dx"). Hydrogel cross-linked with polyacrylamide ("Bulkamid"). Porcine dermal collagen (collagen from pig skin, "Permacol"). Synthetic calcium hydroxylapatite ceramic microspheres. Polyacrylonitrile in cylinder form. aluminum potassium sulfate and tannic acid (ALTA).
Difficulty staying awake Mental confusion Impaired motor functions Impaired reflexes Impaired coordination Impaired balance Dizziness Respiratory depression Low blood pressure Coma Death Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a four-year-old boy who overdosed on clonazepam. The combination of clonazepam and certain barbiturates (for example, amobarbital), at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression. Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.
== Absorption, metabolism and excretion == In the upper small intestine, thiamine phosphate esters present in food are hydrolyzed by alkaline phosphatase enzymes. At low concentrations (<2 μmol l−1), the absorption process is carrier-mediated. At higher concentrations, absorption also occurs via passive diffusion. Active transport can be inhibited by alcohol consumption or by folate deficiency. The majority of thiamine in serum is circulating bound to albumin, with over (90%) in erythrocytes (red blood cells), and is delivered to cells with high metabolic needs—particularly those in the brain, liver, pancreas, heart, and skeletal and smooth muscles, including cardiac muscle cells. A specific binding protein called thiamine-binding protein has been identified in rat serum and is believed to be a hormone-regulated carrier protein important for tissue distribution of thiamine. Uptake of thiamine by cells of the blood and other tissues occurs via active transport and passive diffusion. Two members of the family of transporter proteins encoded by the genes SLC19A2 and SLC19A3 are capable of thiamine transport. In some tissues, thiamine uptake and secretion appear to be mediated by a Na+-dependent transporter and a transcellular proton gradient. Human storage of thiamine is about 25 to 50 mg, with the greatest concentrations in liver, skeletal muscle, heart, brain, and kidneys. ThMP and free (unphosphorylated) thiamine are present in plasma, milk, cerebrospinal fluid, and, it is presumed, all extracellular fluid.
In cancer, the genomes of affected cells are rearranged in complex or unpredictable ways. In addition to single-nucleotide polymorphism arrays identifying point mutations that cause cancer, oligonucleotide microarrays can be used to identify chromosomal gains and losses (called comparative genomic hybridization). These detection methods generate terabytes of data per experiment. The data is often found to contain considerable variability, or noise, and thus Hidden Markov model and change-point analysis methods are being developed to infer real copy number changes. Two important principles can be used to identify cancer by mutations in the exome. First, cancer is a disease of accumulated somatic mutations in genes. Second, cancer contains driver mutations which need to be distinguished from passengers. Further improvements in bioinformatics could allow for classifying types of cancer by analysis of cancer driven mutations in the genome. Furthermore, tracking of patients while the disease progresses may be possible in the future with the sequence of cancer samples. Another type of data that requires novel informatics development is the analysis of lesions found to be recurrent among many tumors.
== "The First Lady of Chromatography" == After graduating, Smolková-Keulemansová joined the Faculty of Sciences at Charles University and focused on analytical chemistry. In the early 1950s, she built a team focused on modern analytical separation methods such as gas chromatography, high-performance liquid chromatography and electromigration. At the same time, she attended an analytical conference in Prague, leading to her finding a volumetric chromatographic device. Her team began to prepare its own device with volumetric detection and constructed a more universal glass thermal conductivity detector, allowing them to analyze a larger variety of gases. Later, this novel detector became part of a commercially available instrument. Because of her innovation and dedication to the field, she began to be referred to as "the first lady of chromatography".
Sources: en.wikipedia.org
== Limitations == With radioligand therapy, there is always the risk of damage to non-cancerous surrounding tissues along with radioisotope toxicity which is always a challenge in determining how to administer and create the radioligand. Furthermore, the radioligand vial is only viable for a limited time and under specific conditions which challenges transport and storage along with feasible application to the patient. Another limitation is the lack of centers that have trained personnel and equipment for radioligand therapy. Furthermore, individual characteristics affect the exact radiosensitivity to the therapy (thus affecting dosimetry) and are hard to predict without radiobiological models.
On 8 December 2023, authorities reportedly denied her transfer request from the Rampton Secure Hospital, a high-security psychiatric facility, to a mainstream prison. She will not be eligible for another assessment until 2026 at the earliest.
This problem however was resolved with the use of so-called self-polishing paints, in which the biocide was released at a slower rate as the seawater reacted with the surface layer of the paint. More recently, copper-based anti-fouling paints have been used because they are less toxic than TBT in aquatic environments, but are only effective against marine animal life, and not so much weed growth. Non-stick coatings contain no biocide but have extremely slippery surfaces which prevents most fouling and makes it easier to clean any fouling that occurs. Natural biocides are found on marine organisms such as coral and sponges and also prevent fouling if applied to a vessel. Creating a difference in electrical charge between the hull and seawater is a common practice in the prevention of fouling. This technology has proven to be effective, but is easily damaged and may be expensive. Finally, microscopic prickles can be added to a coating, and depending on length and distribution have shown the ability to prevent the attachment of most biofouling.
A wide gap exists between developed and developing countries' 3G and 4G cellular coverage, and issues such as dropped calls, delays, and weak signals hamper telecommunications efficacy in rural areas. Even when countries overcome infrastructural challenges, the price of network connectivity can exclude smallholders, poor farmers, and those in remote areas. Similar accessibility and affordability issues exist for digital devices and digital accounts. According to a 2016 GSMA report, of the 750 million-plus farmers in the 69 surveyed countries, about 295 million had a mobile phone; only 13 million had both a mobile phone and a mobile money account. Despite lingering gaps in network coverage, ICT access has skyrocketed in recent years. In 2007, only 1% of people in developing countries used Internet, but by 2015, 40% did. Mobile-broadband subscriptions, which increased thirty-fold between 2005 and 2015, drove much of this growth. As a key enabler of agricultural change, digital infrastructure requires further development, but growing ICT access indicates progress.
=== Laminin N-terminal === Basement membrane assembly is a cooperative process in which laminins polymerise through their N-terminal domain (LN or domain VI) and anchor to the cell surface through their G domains. Netrins may also associate with this network through heterotypic LN domain interactions. This leads to cell signalling through integrins and dystroglycan (and possibly other receptors) recruited to the adherent laminin. This LN domain-dependent self-assembly is considered to be crucial for the integrity of basement membranes, as highlighted by genetic forms of muscular dystrophy containing the deletion of the LN module from the alpha 2 laminin chain. The laminin N-terminal domain is found in all laminin and netrin subunits except laminin alpha 3A, alpha 4 and gamma 2.
Sources: en.wikipedia.org
Dorothy Hodgkin on Nobelprize.org including the Nobel Lecture, 11 December 1964 The X-ray Analysis of Complicated Molecules Portraits of Dorothy Hodgkin at the National Portrait Gallery, London Works by or about Dorothy Hodgkin at the Internet Archive Four interviews with Dorothy Crowfoot Hodgkin recorded between 1987 and 1989 in partnership with the Royal College of Physicians are held in the Medical Sciences Video Archive in the Special Collections at Oxford Brookes University: Professor Dorothy Crowfoot Hodgkin OM FRS in interview with Sir Gordon Wolstenholme: Interview 1 (1987). Professor Dorothy Crowfoot Hodgkin OM FRS in interview with Max Blythe: Interview 2 (1988). Professor Dorothy Crowfoot Hodgkin OM FRS in interview with Max Blythe: Interview 3 (1989). Professor Dorothy Crowfoot Hodgkin OM FRS at home talking with Max Blythe: Interview 4 (1989). Watch a lecture of Dorothy Crowfoot Hodgkin (1910–1994) at the 1988 Nobel Laureates Symposium at the annual meeting of the American Crystallographic Association, Philadelphia Dorothy Hodgkin featured on the BBC Radio 4 program In Our Time on 3 October 2019. "The exceptional life of Dorothy Crowfoot Hodgkin", BBC "Ideas" video, 27 September 2021
On 12 December 1994, the 2nd Battalion (Airborne), 505th Infantry, with the 2nd Platoon of Company C, 307th Engineer Battalion, deployed as part of Operations Safe Haven and Safe Passage. The battalion deployed from Fort Bragg "to restore order" against what American officials termed "Cuban refugees" who had attacked and injured a number of Air Force personnel and one marine while protesting their detainment at Empire Range along the Panama Canal. The battalion participated in the safeguarding of the Cuban refugees, a camp cordon and reorganization, and the active patrolling in and around the refugee camps in and around the Panamanian jungle along the Panama canal for two months. General Engineering support in the area of camp establishment/improvement operations was provided by the Sappers of the habitually associated Task Force Panther Engineer platoon, 2/C-307th. Task Force Panther was commanded by LTC Lloyd J. Austin III, who was later the first African American General to commander of US Central Command and US Secretary of Defense. This support included the planning of camp power requirements, pouring of 78 concrete pads, three-foot bridges, a set of "mock doors" for airborne pre-jump training, and a system of decks for the muddy camp. During the deployment, the paratroopers experienced a 92 °F (33 °C) Christmas Day. They returned to Fort Bragg on 14 February 1995.
The chestnut or sorrel color, genetically considered "red", is caused by one of two recessive alleles at the extension locus (genetics). Extension has three known alleles: the wildtype "E", necessary for the bay and black coat colors, plus two mutations "e" and "ea", both of which are capable of causing the chestnut color. Each individual horse has two copies of the extension gene. If either copy is "E", then the horse will be bay- or black-based. But if the two copies are any combination of "e" and "ea" (e/e, e/ea, or ea/ea), then the horse will be red-based. Alternate extension "ea" is rare and there is no known difference in appearance between it and the more common "e". Because the red color is recessive, two bay or black parents can produce a chestnut foal if both carry "e" or "ea". However, two chestnut parents cannot produce a bay or black foal. The extension locus (genetics) is found on chromosome 3 (ECA3) and is part of the gene that codes for the equine melanocortin 1 receptor (MC1R). This receptor is part of a signalling pathway which when activated causes melanocytes to produce eumelanin, or black pigment, instead of pheomelanin, or red pigment. The two mutant alleles "e" and "ea" code for dysfunctional receptors unable to activate this pathway, so absent "E", only red pigment can be produced. At least one copy of the functional "E" allele is required to activate the signal and produce black pigment.
In the late 6th century, following Justinian I's wars, seven mobile field armies called comitatenses, numbering around 150,000 troops, were deployed around the empire; they remained the finest armies in Europe. They were aided by twenty-five frontier garrisons of approximately 195,000 lower-quality limitanei troops. Additional troops included subsidised allied forces and imperial guard units like the Scholae Palatinae. Naval forces were limited: flotillas were based at key locations, while 30,000 oarsmen were assembled to row 500, mostly requisitioned, transports to support the Vandalic War in Africa in 533. The losses suffered in the 7th-century Arab conquests led to fundamental changes. The field armies were withdrawn into the core Anatolian territories and assigned to settle in specific districts, which became known as themata and eventually replaced the old provinces. The thematic armies, supported by the proceeds of their districts, came to resemble a provincial militia with a small professional core, aided by foreign mercenaries and imperial regiments at Constantinople. To defend against its new Muslim enemy, the navy was similarly reorganised into several provincialised fleets. It became the dominant power in the eastern Mediterranean, with dromons equipped with Greek fire proving crucial on several occasions. As the 8th-century empire stabilised, the thematic militias proved rebellious and only suitable for defensive operations.
== Histiocytic sarcoma complex == The histiocytic sarcoma (HS) complex encompasses a number of distinctive clinical entities which will be described below. Some definitions are in order, and reflect the preferred nomenclature of the writing group of the Histiocyte Society. Histiocytic neoplasia which originates at a single site is called histiocytic sarcoma. This form of histiocytic sarcoma, which is often encountered on the extremities, has the best prognosis if treated early by surgical excision or by amputation of a limb. When spread to distant sites beyond the local lymph node occurs, the disease is then termed disseminated histiocytic sarcoma; this is more likely to occur unnoticed when primary lesions occur in cryptic sites (e.g. spleen, lung, and bone marrow). This latter form of HS is most like malignant histiocytosis (MH). MH is an aggressive, histiocytic neoplasm which arises in multiple sites simultaneously. Most lesions previously defined as MH are probably more correctly termed disseminated HS. The occurrence of true MH is difficult to establish because the lesions often occur in cryptic sites, and the existence of histiocytic neoplasia is only recognized after clinical signs have appeared and disease progression is advanced. HS and MH are capable of widespread metastasis, hence in time the 2 syndromes merge clinically and it is not always possible to differentiate true multicentric origin (MH) from widespread metastasis of disseminated HS. Also, it is never possible to know exactly how long the disease process has been operative.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.